AR094910A1 - COMBINACIONES QUE COMPRENDEN COMPUESTOS ANTAGONISTAS MUSCARÍNICOS - AGONISTAS b2 (MABA) - Google Patents
COMBINACIONES QUE COMPRENDEN COMPUESTOS ANTAGONISTAS MUSCARÍNICOS - AGONISTAS b2 (MABA)Info
- Publication number
- AR094910A1 AR094910A1 ARP140100621A ARP140100621A AR094910A1 AR 094910 A1 AR094910 A1 AR 094910A1 AR P140100621 A ARP140100621 A AR P140100621A AR P140100621 A ARP140100621 A AR P140100621A AR 094910 A1 AR094910 A1 AR 094910A1
- Authority
- AR
- Argentina
- Prior art keywords
- muscarinic antagonist
- agonistas
- maba
- combinations
- antagonist compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Reivindicación 1: Una combinación que comprende (a) un corticosteroide y (b) un compuesto dual antagonista muscarínico - agonista b2 adrenérgico que es hidroxi(di-2-tienil)acetato de trans-4-[{2-[({[2-cloro-4-({[(2R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-iI)etil]amino}metil)-5-metoxifenil]amino}carbonil)oxi]etil}-(metil)amino]ciclohexilo, o cualquier sal o solvato farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13382060 | 2013-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR094910A1 true AR094910A1 (es) | 2015-09-09 |
Family
ID=47827112
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140100622A AR094911A1 (es) | 2013-02-27 | 2014-02-27 | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃ |
ARP140100621A AR094910A1 (es) | 2013-02-27 | 2014-02-27 | COMBINACIONES QUE COMPRENDEN COMPUESTOS ANTAGONISTAS MUSCARÍNICOS - AGONISTAS b2 (MABA) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140100622A AR094911A1 (es) | 2013-02-27 | 2014-02-27 | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃ |
Country Status (33)
Country | Link |
---|---|
US (1) | US9562039B2 (es) |
EP (1) | EP2961407B1 (es) |
JP (1) | JP6364429B2 (es) |
KR (1) | KR102002668B1 (es) |
CN (1) | CN105025897B (es) |
AR (2) | AR094911A1 (es) |
AU (1) | AU2014222645B2 (es) |
BR (1) | BR112015020152B1 (es) |
CA (1) | CA2901865C (es) |
CL (1) | CL2015002402A1 (es) |
CR (1) | CR20150427A (es) |
DK (1) | DK2961407T3 (es) |
DO (1) | DOP2015000197A (es) |
EA (1) | EA028566B1 (es) |
ES (1) | ES2674085T3 (es) |
HK (1) | HK1212246A1 (es) |
HR (1) | HRP20181097T1 (es) |
HU (1) | HUE039303T2 (es) |
IL (1) | IL240278B (es) |
LT (1) | LT2961407T (es) |
MX (2) | MX2015010680A (es) |
MY (1) | MY180350A (es) |
PE (1) | PE20151602A1 (es) |
PH (1) | PH12015501754B1 (es) |
PL (1) | PL2961407T3 (es) |
PT (1) | PT2961407T (es) |
RS (1) | RS57297B1 (es) |
SG (1) | SG11201505868QA (es) |
SI (1) | SI2961407T1 (es) |
TW (1) | TWI643853B (es) |
UY (1) | UY35355A (es) |
WO (1) | WO2014131851A1 (es) |
ZA (1) | ZA201505374B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2419610C2 (ru) | 2005-05-26 | 2011-05-27 | Ньюрон Системз, Инк. | Композиции и способы лечения заболевания сетчатки |
ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
JP6307091B2 (ja) | 2012-12-18 | 2018-04-04 | アルミラル・ソシエダッド・アノニマAlmirall, S.A. | β2アドレナリンアゴニスト活性およびM3ムスカリンアンタゴニスト活性を有する新規のシクロヘキシルおよびキヌクリジニルカルバメート誘導体 |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
US10149823B2 (en) | 2013-04-30 | 2018-12-11 | Otitopic Inc. | Dry powder formulations and methods of use |
TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有maba化合物和皮質類固醇之組合 |
TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽 |
TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物 |
KR102398639B1 (ko) * | 2017-06-20 | 2022-05-17 | (주) 성운파마코피아 | 아미드 유도체의 염 및 그 제조방법 |
JP2021502954A (ja) | 2017-09-22 | 2021-02-04 | オティトピック インク. | ステアリン酸マグネシウムを含む乾燥粉末組成物 |
US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
CA3077362A1 (en) | 2017-10-10 | 2019-04-18 | Aldeyra Therapeutics, Inc. | Treatment of inflammatory disorders |
AU2019319740A1 (en) | 2018-08-06 | 2021-03-25 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
WO2020244452A1 (zh) * | 2019-06-06 | 2020-12-10 | 中国医药研究开发中心有限公司 | 具有β 2受体激动及M受体拮抗活性的杂环衍生物及其医药用途 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1212742B (it) | 1983-05-17 | 1989-11-30 | Dompe Farmaceutici Spa | Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica |
EP0147475B1 (en) | 1983-09-26 | 1987-03-18 | MAGIS FARMACEUTICI S.p.A. | Aminocyclohexanol derivatives having an expectorant activity, process for their preparation and pharmaceutical compositions containing them |
CA2024789C (en) | 1989-09-07 | 2001-02-06 | Malcolm Johnson | Compounds for the treatment of inflammation and allergy |
GB9020051D0 (en) | 1990-09-13 | 1990-10-24 | Pfizer Ltd | Muscarinic receptor antagonists |
WO1998009632A1 (en) | 1996-09-06 | 1998-03-12 | Merck & Co., Inc. | Methods and compositions for treating preterm labor |
SE9704644D0 (sv) | 1997-12-12 | 1997-12-12 | Astra Ab | New use |
US6673908B1 (en) | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
HU228503B1 (hu) | 1999-08-20 | 2013-03-28 | Dow Agrosciences Llc | Gombaölõ heterociklusos aromás amidok, ezeket tartalmazó készítmények és eljárás alkalmazásukra |
PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
JP4767842B2 (ja) | 2003-04-01 | 2011-09-07 | セラヴァンス, インコーポレーテッド | β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物 |
EP1626970B1 (en) | 2003-05-28 | 2009-07-08 | Theravance, Inc. | Azabicycloalkane compounds as muscarinic receptor antagonists |
US7320990B2 (en) | 2004-02-13 | 2008-01-22 | Theravance, Inc. | Crystalline form of a biphenyl compound |
DE102004024453A1 (de) | 2004-05-14 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen |
ES2251867B1 (es) | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
TWI374883B (en) | 2004-08-16 | 2012-10-21 | Theravance Inc | Crystalline form of a biphenyl compound |
JP2008510014A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス, インコーポレーテッド | β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
JP2008510015A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス, インコーポレーテッド | β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
RU2442771C2 (ru) | 2005-08-08 | 2012-02-20 | Арджента Дискавери Лтд | Производные бицикло[2,2,1]гепт-7-иламина и их применения |
GB0602778D0 (en) | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
NZ570693A (en) | 2006-03-20 | 2011-02-25 | Pfizer Ltd | Amine derivatives |
GB0613154D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
GB0702384D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | Chemical compounds |
WO2008017827A2 (en) | 2006-08-08 | 2008-02-14 | Argenta Discovery Limited | Azole and thiazole derivatives and their uses |
EP1894568A1 (en) | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
AP2009004791A0 (en) | 2006-10-04 | 2009-04-30 | Pfizer Ltd | Sulfonamide derivatives as adrenergic agonists andmuscarinic antagonists |
GB0700972D0 (en) | 2007-01-18 | 2007-02-28 | Imp Innovations Ltd | Treatment of inflammatory disease |
GB0702413D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New chemical compounds |
WO2008096129A1 (en) | 2007-02-07 | 2008-08-14 | Argenta Discovery Ltd | Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors |
WO2008149110A1 (en) | 2007-06-08 | 2008-12-11 | Argenta Discovery Limited | Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated |
PE20090907A1 (es) | 2007-07-21 | 2009-08-05 | Boehringer Ingelheim Int | Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente |
WO2009017813A1 (en) | 2007-08-02 | 2009-02-05 | Teva Pharmaceutical Industries Ltd. | O-desmethyl venlafaxine saccharinate |
US8148373B2 (en) | 2008-02-06 | 2012-04-03 | Astrazeneca Ab | Compounds |
CN101544572B (zh) | 2008-03-26 | 2013-03-20 | 连云港恒邦医药科技有限公司 | 一种氨溴索衍生物及其制备方法 |
GB0808708D0 (en) | 2008-05-13 | 2008-06-18 | Astrazeneca Ab | New compounds 274 |
US8263623B2 (en) | 2008-07-11 | 2012-09-11 | Pfizer Inc. | Triazol derivatives useful for the treatment of diseases |
WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
NZ595850A (en) | 2009-04-23 | 2013-05-31 | Theravance Inc | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND Beta2 ADRENERGIC RECEPTOR AGONIST ACTIVITY |
JP5379224B2 (ja) | 2009-04-30 | 2013-12-25 | 帝人ファーマ株式会社 | 四級アンモニウム塩化合物 |
GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
EP2386555A1 (en) * | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
AR083115A1 (es) | 2010-09-30 | 2013-01-30 | Theravance Inc | Sales oxalato cristalinas de un compuesto diamida |
GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
WO2012168359A1 (en) | 2011-06-10 | 2012-12-13 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
CN103547575B (zh) | 2011-06-10 | 2016-08-17 | 奇斯药制品公司 | 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物 |
MX351299B (es) | 2011-11-11 | 2017-10-10 | Pfizer | 2-tiopirimidinonas. |
EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
UA116622C2 (uk) | 2011-11-11 | 2018-04-25 | Аллерган, Інк. | Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей |
EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
AU2012335088B2 (en) | 2011-11-11 | 2017-08-24 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
BR112015012746A2 (pt) | 2012-12-06 | 2017-07-11 | Chiesi Farm Spa | compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos |
UA118181C2 (uk) | 2012-12-06 | 2018-12-10 | К'Єзі Фармачеутічі С.П.А. | Сполуки, які мають активність антагоністів мускаринових рецепторів і агоністів бета-2 адренергічних рецепторів |
JP6307091B2 (ja) | 2012-12-18 | 2018-04-04 | アルミラル・ソシエダッド・アノニマAlmirall, S.A. | β2アドレナリンアゴニスト活性およびM3ムスカリンアンタゴニスト活性を有する新規のシクロヘキシルおよびキヌクリジニルカルバメート誘導体 |
TW201440768A (zh) | 2013-02-27 | 2014-11-01 | Almirall Sa | 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物 |
TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽 |
TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有maba化合物和皮質類固醇之組合 |
TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物 |
-
2014
- 2014-02-26 TW TW103106585A patent/TWI643853B/zh not_active IP Right Cessation
- 2014-02-27 CA CA2901865A patent/CA2901865C/en active Active
- 2014-02-27 CR CR20150427A patent/CR20150427A/es unknown
- 2014-02-27 RS RS20180657A patent/RS57297B1/sr unknown
- 2014-02-27 EA EA201500875A patent/EA028566B1/ru not_active IP Right Cessation
- 2014-02-27 DK DK14706652.6T patent/DK2961407T3/en active
- 2014-02-27 PL PL14706652T patent/PL2961407T3/pl unknown
- 2014-02-27 AR ARP140100622A patent/AR094911A1/es unknown
- 2014-02-27 JP JP2015559499A patent/JP6364429B2/ja not_active Expired - Fee Related
- 2014-02-27 EP EP14706652.6A patent/EP2961407B1/en active Active
- 2014-02-27 SI SI201430710T patent/SI2961407T1/en unknown
- 2014-02-27 UY UY35355A patent/UY35355A/es not_active Application Discontinuation
- 2014-02-27 WO PCT/EP2014/053871 patent/WO2014131851A1/en active Application Filing
- 2014-02-27 ES ES14706652.6T patent/ES2674085T3/es active Active
- 2014-02-27 MY MYPI2015702824A patent/MY180350A/en unknown
- 2014-02-27 PT PT147066526T patent/PT2961407T/pt unknown
- 2014-02-27 AU AU2014222645A patent/AU2014222645B2/en not_active Ceased
- 2014-02-27 MX MX2015010680A patent/MX2015010680A/es unknown
- 2014-02-27 PE PE2015001752A patent/PE20151602A1/es not_active Application Discontinuation
- 2014-02-27 AR ARP140100621A patent/AR094910A1/es unknown
- 2014-02-27 SG SG11201505868QA patent/SG11201505868QA/en unknown
- 2014-02-27 HU HUE14706652A patent/HUE039303T2/hu unknown
- 2014-02-27 CN CN201480011023.0A patent/CN105025897B/zh not_active Expired - Fee Related
- 2014-02-27 BR BR112015020152-0A patent/BR112015020152B1/pt not_active IP Right Cessation
- 2014-02-27 MX MX2015010679A patent/MX358624B/es active IP Right Grant
- 2014-02-27 US US14/770,206 patent/US9562039B2/en active Active
- 2014-02-27 LT LTEP14706652.6T patent/LT2961407T/lt unknown
- 2014-02-27 KR KR1020157023407A patent/KR102002668B1/ko active IP Right Grant
-
2015
- 2015-07-24 ZA ZA2015/05374A patent/ZA201505374B/en unknown
- 2015-07-30 IL IL240278A patent/IL240278B/en active IP Right Grant
- 2015-08-10 PH PH12015501754A patent/PH12015501754B1/en unknown
- 2015-08-14 DO DO2015000197A patent/DOP2015000197A/es unknown
- 2015-08-26 CL CL2015002402A patent/CL2015002402A1/es unknown
-
2016
- 2016-01-13 HK HK16100349.0A patent/HK1212246A1/xx not_active IP Right Cessation
-
2018
- 2018-07-11 HR HRP20181097TT patent/HRP20181097T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR094910A1 (es) | COMBINACIONES QUE COMPRENDEN COMPUESTOS ANTAGONISTAS MUSCARÍNICOS - AGONISTAS b2 (MABA) | |
AR110381A2 (es) | Inhibidores biarilo de tirosina cinasa de bruton | |
CO2018006714A2 (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
NI201600098A (es) | Composiciones farmacéuticas que comprenden azd9291 | |
AR090456A1 (es) | Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos | |
CL2016001576S1 (es) | Instrumento para secuenciar formado por un cuerpo prismático de cara frontal inclinada, la mitad superior tiene dos porciones de cara superior inclinada, la porción izquierda sobresale hacia adelante y la mitad inferior de la cara frontal inclinada posee una porción resaltada de frente rectangular. | |
BR112015022972A2 (pt) | composição farmacêutica de cloridrato de s-cetamina | |
CU20150020A7 (es) | Composición farmacéutica recubierta que contiene regorafenib | |
BR112016009889A2 (pt) | ?compostos agonistas duplos gip-glp-1 e métodos? | |
AR077629A1 (es) | Mimetico de smac | |
BR112016011755A2 (pt) | derivado de ureia ou sal farmacologicamente aceitável do mesmo | |
BR112015020466A2 (pt) | inibidores de cdc7 | |
BR112015019587A2 (pt) | combinações compreendendo compostos maba e corticosteroides | |
MY182884A (en) | Pyrazole-amide compound and medicinal uses therefor | |
UY35684A (es) | Formulación de inhibidores de la tirosina quinasa de bazo (syk) | |
BR112017011309A2 (pt) | fechamento de uma câmara de um recipiente para um produto farmacêutico | |
CR20160477A (es) | Nanopartículas terapéuticas que comprenden un agente terapéutico, y métodos para su elaboración y uso | |
UY35677A (es) | Combinaciones que comprenden compuestos maba y corticosteroides | |
AR102767A1 (es) | Inhibidores de ezh2 | |
BR112015021984A2 (pt) | estrutura de restrição de detritos de córrego | |
BR112014025041B8 (pt) | Composição farmacêutica | |
AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
WO2014153009A3 (en) | Thiosaccharide mucolytic agents | |
BR112013022213A2 (pt) | administração parenteral de tapentadol | |
EP3995489A3 (en) | Disulfide compounds for delivery of pharmaceutical agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |